[1] Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol, 2020, 73(1): 202-209. [2] Eslam M, Sanyal AJ, George J, et al. MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease.BMC Gastroenterol, 2020, 158(7): 1999-2014. [3] Hassen G, Singh A, Belete G, et al. Nonalcoholic fatty liver disease: an emerging modern-day risk factor for cardiovascular disease. Cureus, 2022, 14(5): e25495. [4] Gutiérrez-Cuevas J, Santos A, Armendariz-Borunda J. Pathophysiological molecular mechanisms of obesity: a link between mafld and nash with cardiovascular diseases. Int J Mol Sci, 2021,22(21):11629. [5] Dobiásová M, Frohlich J. The plasma parameter log (TG/HDL-C) as an atherogenic index: correlation with lipoprotein particle size and esterification rate in apoB-lipoprotein-depleted plasma. Clin Biochem, 2001, 34(7):583-588. [6] Dobiásová M. AIP--atherogenic index of plasma as a significant predictor of cardiovascular risk: from research to practice. Vnitr Lek, 2006, 52(1): 64-71. [7] Niroumand S, Khajedaluee M, Khadem-Rezaiyan M, et al. Atherogenic index of plasma (AIP): A marker of cardiovascular disease. Med J Islam Repub Iran, 2015,29:240. [8] Ngu NLY, Flanagan E, Bell S, et al. Acute-on-chronic liver failure: Controversies and consensus. World J Gastroenterol, 2023,29(2):232-240. [9] Xie F, Zhou H, Wang Y. Atherogenic index of plasma is a novel and strong predictor associated with fatty liver: a cross-sectional study in theChinese han population. Lipids Health Dis,2019,18(1):170. [10] Wang Q, Zheng D, Liu J,et al. Atherogenic index of plasma is a novel predictor of non-alcoholic fatty liver disease in obese participants: a cross-sectional study. Lipids Health Dis, 2018, 17(1): 284. [11] Dong BY, Mao YQ, Li ZY, et al. The value of the atherogenic index of plasma in non-obese people with non-alcoholic fatty liver disease: a secondary analysis based on a cross-sectional study. Lipids Health Dis, 2020,19(1):148. [12] Duan SJ, Ren ZY, Zheng T, et al. Atherogenic index of plasma combined with waist circumference and body mass index to predict metabolic-associated fatty liver disease. World J Gastroenterol, 2022,28(36):5364-5370. [13] Ismaiel A, Ciobanu OS, Ismaiel M, et al. Atherogenic index of plasma in non-alcoholic fatty liver disease: systematic review and meta-analysis. Biomedicines, 2022, 10(9): 2101. [14] Lonardo A, Nascimbeni F, Ballestri S, et al. Sex differences in nonalcoholic fatty liver disease: state of the art and identification of research gaps.Hepatology, 2019,70(4):1457-1469. [15] Andronescu CI, Purcarea MR, Babes PA. Nonalcoholic fatty liver disease: epidemiology, pathogenesis and therapeutic implications. J Med Lif, 2018,11(1):20-23. [16] Liu J, Zhou L, An Y, et al. The atherogenic index of plasma: A novel factor more closely related to non-alcoholic fatty liver disease than other lipid parameters in adults. Front Nutr, 2022, 9: 954219. [17] Lovejoy JC, Champagne CM, de Jonge L, et al. Increased visceral fat and decreased energy expenditure during the menopausal transition. Int J Obes (Lond), 2008,32(6):949-958. [18] DiStefano JK. NAFLD and NASH inpostmenopausal women: Implications for diagnosis and treatment. Endocrinology, 2020,161(10):bqaa134. [19] Huxley RR, Barzi F, Lam TH, et al. Isolated low levels of high-density lipoprotein cholesterol are associated with an increased risk of coronary heart disease: an individual participant data meta-analysis of 23 studies in the Asia-Pacific region. Circulation, 2011, 124(19): 2056-2064. [20] Giannini C, Santoro N, Caprio S, et al. The triglyceride-to-HDL cholesterol ratio: association with insulin resistance in obese youths of different ethnic backgrounds. Diabetes Care, 2011, 34(8): 1869-1874. |